Skip to main content Accessibility help
×
Home

Through the Skin, To the Nerves: Subcutaneous Immunoglobulin for Neuromuscular Diseases

  • Hans D. Katzberg (a1)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Through the Skin, To the Nerves: Subcutaneous Immunoglobulin for Neuromuscular Diseases
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Through the Skin, To the Nerves: Subcutaneous Immunoglobulin for Neuromuscular Diseases
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Through the Skin, To the Nerves: Subcutaneous Immunoglobulin for Neuromuscular Diseases
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

References

Hide All
1. Suleman, A, Theoret, L, Bourque, P, Pringle, E, Cameron, DW, Cowan, J. Evaluation of a personalized subcutaneous immunoglobulin treatment program for neurological patients. Can J Neurol Sci. 2019;46(1):38-43.
2. Markvardsen, LH, Harbo, T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. J Neurol Sci. 2017;378:19-25.
3. Markvardsen, LH, Harbo, T, Sindrup, SH, et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2014;21(12):1465-1470.
4. Cocito, D, Merola, A, Peci, E, et al. SCIg and Chronic Dysimmune Neuropathies Italian Network. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. J Neurol. 2014;261(11):2159-2164.
5. Katzberg, HD, Rasutis, V, Bril, V. Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy. Muscle Nerve. 2016;54(5):856-863.
6. Bourque, PR, Pringle, CE, Cameron, W, Cowan, J, Chardon, JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study. PLoS One. 2016;11(8):e0159993.
7. van Schaik, IN, Bril, V, van Geloven, N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46.
8. Beecher, G, Anderson, D, Siddiqi, ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial. Neurology. 2017;89(11):1135-1141.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed